哌拉西林钠他唑巴坦钠注射剂联合地塞米松注射液治疗社区获得性肺炎伴发热的临床研究  

Clinical trial of piperacillin sodium and tazobactam sodium for injection combined with dexamethasone injection in the treatment of community acquired pneumonia with fever

作　　者：吴滨[1] 赵荣娟[1] 

机构地区：[1]浙江萧山医院呼吸内科,浙江萧山311200

出　　处：《中国临床药理学杂志》2017年第4期291-293,300,共4页The Chinese Journal of Clinical Pharmacology

基　　金：杭州市科技计划引导基金资助项目(2013ZJXSYY03)

摘　　要：目的观察哌拉西林钠他唑巴坦钠注射液联合地塞米松注射液治疗社区获得性肺炎伴发热的临床疗效和安全性。方法将56例社区获得性肺炎伴发热患者随机分为对照组28例和试验组28例。对照组予以哌拉西林钠他唑巴坦钠每次4.5 g,bid,静脉滴注;试验组在对照组治疗的基础上,予以地塞米松每次5 mg,qd,静脉滴注,连续使用3 d。2组患者均治疗10 d。比较2组患者的临床疗效、血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、IL-10,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为96.43%(27/28例)和78.57%(22/28例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的体温分别为(37.35±1.63),(38.42±1.72)℃;TNF-α分别为(90.56±12.76),(125.25±16.45)pg·mL^(-1);IL-6分别为(42.56±3.22),(74.79±4.73)pg·mL^(-1);IL-10分别为(19.76±0.35),(36.35±1.64)pg·mL^(-1),差异均有统计学意义(P<0.05)。试验组的药物不良反应主要有恶心、腹泻、头晕,对照组的药物不良反应主要有腹泻、头晕、注射部位疼痛。试验组和对照组的药物不良反应发生率分别为14.29%和10.71%,差异无统计学意义(P>0.05)。结论哌拉西林钠他唑巴坦钠联合地塞米松治疗社区获得性肺炎伴发热的临床疗效显著,能明显地减轻患者的炎症反应,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of piperacillin sodium and tazobactam sodium for injection combined with dexamethasone in the treatment of community acquired pneumonia with fever. Methods Fifty- six patients with community acquired pneumonia with fever were randomly divided into control group（ n = 28 cases） and treatment group（ n = 28 cases）. Control group was given intravenous infusion of piperacillin sodium and tazobactam sodium for injection 4. 5 g bid. Treatment group was treated with intravenous infusion of dexamethasone 5 mg qd with continuous use for 3 d,on the basis of the control group.Two groups were treated for 10 d. The clinical efficacy,serum tumor necrosis factor- α（ TNF- α）,interleukin- 6（ IL- 6）,IL- 10 and adverse drug reactions were compared between two groups. Results Aftertreatment,the total effective rates in treatment and control groups were 96. 43%（ 27 /28 cases） and 78. 57%（ 22 /28cases） with significant difference（ P〈0. 05）. After treatment,the main indexes in treatment and control groups were compared： the temperature were（ 37. 35 ± 1. 63）,（ 38. 42 ± 1. 72） ℃; TNF- α were（ 90. 56 ± 12. 76）,（ 125. 25 ± 16. 45） pg ·mL^-1 IL- 6 were（ 42. 56 ± 3. 22）,（ 74. 79 ± 4. 73） pg ·mL^-1 IL- 10 were（ 19. 76 ± 0. 35）,（ 36. 35 ± 1. 64） pg·mL^-1the differences were significant（ P〈0. 05）. The drug adverse reactions in treatment group were based on mainly nausea,diarrhea and dizziness,which in the control group were based on diarrhea,dizziness and injection site pain. The incidences of adverse drug reactions in treatment and control groups were 14. 29% and 10. 71% without significant difference（ P〉0. 05）. Conclusion Piperacillin sodium and tazobactam sodium for injection combined with dexamethasone has a definitive clinical efficacy in the treatment of community acquired pneumonia with fever,which can reduce the inflammatory response,without increasing the incidence of adverse drug reactions.

关 键 词：注射用哌拉西林钠他唑巴坦钠 地塞米松 社区获得性肺炎 发热 安全性 

分 类 号：R978.1[医药卫生—药品]